LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. (Q34090699)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. |
scientific article |
Statements
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction (English)
Stephen G Ellis
Jay H Traverse
Timothy D Henry
Douglas E Vaughan
Carl J Pepine
James T Willerson
David X M Zhao
Lara M Simpson
Marc S Penn
Barry J Byrne
Emerson C Perin
Adrian P Gee
Antonis K Hatzopoulos
David H McKenna
John R Forder
Doris A Taylor
Christopher R Cogle
Sarah Baraniuk
Rachel E Olson
Beth C Jorgenson
Shelly L Sayre
Rachel W Vojvodic
David J Gordon
Sonia I Skarlatos
Lemuel A Moyè
Robert D Simari
Cardiovascular Cell Therapy Research Network
1 January 2010
1 reference
1 reference
1 reference
1 reference
1 reference